CD147, MMP-1, MMP-2 and MMP-9 protein expression as significant prognostic factors in human prostate cancer.
OBJECTIVE
CD147 and MMPs have been demonstrated to be involved in tumor invasion and angiogenesis. The aim of this study was to analyze the clinicopathological significance of CD147, MMP-1, MMP-2 and MMP-9 expression in human prostate cancer (PCa) and to evaluate their involvement in the progression of PCa.


METHODS
CD147, MMP-1, MMP-2 and MMP-9 expression was assessed in paraffin-embedded specimens collected from 62 cases of PCa and 15 cases of benign prostatic hyperplasia (BPH) by immunohistochemistry. Spearman's correlation was applied to determine possible relationships between CD147, MMP-1, MMP-2 and MMP-9 expression and PCa. The association of CD147 and MMP-2 protein expression with the clinicopathological characteristics and the prognosis of PCa was subsequently assessed.


RESULTS
CD147was expressed in 51/62 (82.3%) PCa patients and in 2/15 (13.3%) BPH cases. MMP-1, MMP-2 and MMP-9 expression was significantly higher in PCa tissue than in BPH tissue. Using Spearman analysis, a significant positive correlation between CD147 and MMP-1, MMP-2 and MMP-9 expression was found (p <0.05). CD147 and MMP-2 expression was correlated with TMN grade and Gleason score. Patients with concurrent expression of CD147+ and MMP-2+ had the lowest survival (p <0.01).


CONCLUSIONS
The results suggest that concurrent expression of CD147 and MMP may be an important characteristic of PCa which may help in the prediction of PCa progression.
Zhong
Wei-de
WD
Guangzhou First Municipal People's Hospital, Affiliated Guangzhou Medical College, Guangzhou, China. wdezhong@21cn.com
Han
Zhao-dong
ZD
He
Hui-chan
HC
Bi
Xue-cheng
XC
Dai
Qi-shan
QS
Zhu
Gang
G
Ye
Yong-kang
YK
Liang
Yu-xiang
YX
Qin
Wei-jun
WJ
Zhang
Ze
Z
Zeng
Guo-hua
GH
Chen
Zhi-nan
ZN
D000368:Aged; D000369:Aged, 80 and over; D051926:Basigin / Q000378:metabolism*; D014408:Biomarkers, Tumor; D018450:Disease Progression; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D007124:Immunoenzyme Techniques; D008297:Male; D020781:Matrix Metalloproteinase 1 / Q000378:metabolism*; D020778:Matrix Metalloproteinase 2 / Q000378:metabolism*; D020780:Matrix Metalloproteinase 9 / Q000378:metabolism*; D008875:Middle Aged; D009367:Neoplasm Staging; D011379:Prognosis; D011467:Prostate / Q000378:metabolism / Q000473:pathology; D011470:Prostatic Hyperplasia / Q000378:metabolism / Q000473:pathology / Q000601:surgery; D011471:Prostatic Neoplasms / Q000378:metabolism* / Q000473:pathology / Q000601:surgery
C497886:BSG protein, human; D014408:Biomarkers, Tumor; D051926:Basigin; D020778:Matrix Metalloproteinase 2; D020780:Matrix Metalloproteinase 9; D020781:Matrix Metalloproteinase 1